Irmak 2014.

Methods	A patient report of phobias and visual hallucinations during methylphenidate treatment
Participants	Diagnosis of ADHD: DSM‐IV (subtype: combined) Age: 9 years old IQ: WİSC‐R: performance IQ: 78, verbal IQ: 87 Sex: male Ethnicity: not stated Country: Turkey Comorbidity: Moebius syndrome Comedication: none Sociodemographics: not stated
Interventions	Methylphenidate type: osmotic release oral system (OROS) Methylphenidate dosage: gradually titrated up to 1 mg/kg Administration schedule: not stated Duration of treatment: not stated Treatment compliance: not stated
Outcomes	Serious adverse events: Methylphenidate prescribed at initial ADHD diagnosis, then withdrawn following the onset of phobias and visual hallucinations as well as lack of improvement in attention problems
Notes	Key conclusions of the study authors: dramatic occurrence of adverse effects in our patients suggests that there is an increased vulnerability to adverse effects of methylphenidate in patients with syndromes when compared to other ADHD patients Supplemental information regarding ADHD diagnosis, IQ and comedication received through personal email correspondence with the authors in June 2016 (Irmak 2016 [pers comm])